Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal therapy, consisting mostly of a combination of surgery, radiother...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson, Joshua R. D., Cuzzubbo, Stefania, McArthur, Simon, Durrant, Lindy G., Adhikaree, Jason, Tinsley, Chris J., Pockley, A. Graham, McArdle, Stephanie E. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594513/
https://www.ncbi.nlm.nih.gov/pubmed/33178210
http://dx.doi.org/10.3389/fimmu.2020.582106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594513/
https://www.ncbi.nlm.nih.gov/pubmed/33178210
http://dx.doi.org/10.3389/fimmu.2020.582106

Ejemplares similares